Additionally, treatments that reduce IL-6 could lower AF risk: in the CANTOS trial, a secondary analysis found a reduction in hospitalizations for AF in the treated group, which may indicate a benefit of attenuating the inflammatory cascade on atrial arrhythmogenesis [95]. This evidence concerns the gene IL6 and atrial fibrillation.